Results 31 to 40 of about 1,213 (179)
Objective To analyze ABO system hemolytic disease of the fetus and newborn (HDFN) and its influencing factors in Obstetrics Department of our hospital.
Shuling DONG +5 more
doaj +1 more source
The unusual abundance of a rare finding!
We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature.
Rahaf Altahan, Areej Al Mugairi
doaj +1 more source
BACKGROUND: Clinical manifestations of hemolytic disease of the fetus and newborn include anemia, hyperbilirubinemia, hydrops fetalis, kernicterus, and fetal or neonatal demise.
Alexis A. Krumme, ScD +6 more
doaj +1 more source
Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes
Background Advances in postnatal care for hemolytic disease of the fetus and newborn (HDFN) have occurred over the past decades, but little is known regarding the frequency of postnatal treatment and the clinical outcomes of affected neonates.
Derek P. de Winter +4 more
doaj +1 more source
Anti-E alloimmunization in a pregnancy with a low antibody titer
Red blood cell alloimmunization during pregnancy causes hemolytic disease of the fetus and newborn. While alloimmunization in pregnancy is treatable with anti-D antibodies, management with other antibodies has not been studied.
K. Nakanishi +8 more
doaj +1 more source
Cold reacting anti‐M causing delayed hemolytic disease of the newborn [PDF]
BACKGROUND: Hemolytic disease of the fetus and newborn (HDFN) is due to passively transferred maternal antibodies directed against fetal red blood cell (RBC) antigens and can lead to severe morbidity and mortality.
Philip Crispin +11 more
core +1 more source
Anti-M Alloimmunization: Management and Outcome at a Single Institution
Objective The objective of this study was to review the management strategies and outcomes in gravidas with anti-M alloimmunization over 15 years. Study Design Data collected from 195 pregnant patients with anti-M antibodies from July 2000 ...
Bethany Stetson +2 more
doaj +1 more source
A biomimetic ultrasound‐responsive piRNA delivery nanoparticle platform (piR‐NPs) enables targeted delivery and ultrasound (US)‐triggered release of piR‐1873 in infarcted myocardium. The released piR‐1873 suppresses Usp2‐mediated RIP1/RIP3/MLKL necroptosis, reduces myocardial injury and fibrosis, and promotes cardiac functional recovery, providing a ...
Yajun Zhang +10 more
wiley +1 more source
Delayed Recognition of Maternal G6PD Heterozygous Status Across Prenatal and Newborn Care Interfaces
ABSTRACT Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is the most common red blood cell enzymatic disorder worldwide. Although many heterozygotes are asymptomatic, affected neonates have an increased risk for hyperbilirubinemia and related complications.
Mona M. Makhamreh +5 more
wiley +1 more source
The molecular pathology of hemolytic disease of the fetus and newborn (HDFN) is determined by different RHD, RHCE, and KEL genotypes and by blood group incompatibility between the mother and fetus that is caused by erythrocyte antigen presence/absence on
Radek Vodicka +5 more
doaj +1 more source

